A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Condition(s):Polycystic Ovary SyndromeLast Updated:September 28, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Polycystic Ovary SyndromeLast Updated:September 28, 2023Completed
Condition(s):Congenital Adrenal Hyperplasia; 21-OHDLast Updated:January 20, 2023Recruiting
Condition(s):Congenital Adrenal HyperplasiaLast Updated:January 24, 2024Active, not recruiting
Condition(s):Congenital Adrenal HyperplasiaLast Updated:January 8, 2024Active, not recruiting
Condition(s):Congenital Adrenal Hyperplasia; CAH – Congenital Adrenal Hyperplasia; CAH – 21-Hydroxylase DeficiencyLast Updated:January 30, 2020Completed
Condition(s):Congenital Adrenal Hyperplasia; CAH – Congenital Adrenal HyperplasiaLast Updated:June 26, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.